{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:37:32Z","timestamp":1790703452705,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Because of the limited number of subjects in prelicensure studies, autoimmune diseases and other rare adverse effects of vaccines may go undetected. Since 2006, millions of human papillomavirus (HPV) vaccine doses have been distributed and a considerable amount of postlicensure safety data has been generated. The objective of this study was to review available HPV postlicensure safety studies and to summarize risk estimates of autoimmune and other rare diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>For this systematic review and meta-analysis, we searched literature databases to identify any postlicensure safety studies related to HPV vaccination and autoimmune adverse events from inception to April 16, 2019. Pooled risk estimates were computed using fixed- or random-effects models if at least 2 estimates per disease and per HPV vaccine were available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-two studies met our inclusion criteria. The studies applied various methodologies and used different types of data sources and outcome definitions. Quadrivalent HPV vaccine (4vHPV) was most commonly assessed. Type 1 diabetes mellitus, immune thrombocytopenia purpura and thyroiditis diseases were most frequently reported. The meta-analysis was conducted on 35 diseases corresponding to 48 pooled risk estimates. Majority of the pooled estimates showed no significant effect (n = 43). Three negative (paralysis, immune thrombocytopenia purpura and chronic fatigue syndrome) and 2 positive (Hashimoto and Raynaud diseases) associations were detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our study demonstrated an absence of clear association between HPV vaccines and autoimmune and other rare diseases. The review also highlights the need for more systematic collaborations to monitor rare safety adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000002569","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T15:48:51Z","timestamp":1577375331000},"page":"287-293","source":"Crossref","is-referenced-by-count":28,"title":["Systematic Review and Meta-analysis of Postlicensure Observational Studies on Human Papillomavirus Vaccination and Autoimmune and Other Rare Adverse Events"],"prefix":"10.1097","volume":"39","author":[{"given":"Corinne","family":"Willame","sequence":"first","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartini","family":"Gadroen","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Erasmus MC, University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichor","family":"Bramer","sequence":"additional","affiliation":[{"name":"Medical Library, Erasmus MC, University Medical Center, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weibel","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Erasmus MC, University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Sturkenboom","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"e009915","DOI":"10.1136\/bmjopen-2015-009915","article-title":"Continuing reductions in HPV 16\/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study.","volume":"6","author":"Mesher","year":"2016","journal-title":"BMJ Open"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/ijc.30035","article-title":"Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: a population-based study.","volume":"138","author":"Herweijer","year":"2016","journal-title":"Int J Cancer"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/jcm4040614","article-title":"Safety and efficacy data on vaccines and immunization to human papillomavirus.","volume":"4","author":"Kash","year":"2015","journal-title":"J Clin Med"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jadohealth.2011.07.003","article-title":"The efficacy and safety of the quadrivalent human papillomavirus 6\/11\/16\/18 vaccine gardasil.","volume":"49","author":"Haupt","year":"2011","journal-title":"J Adolesc Health"},{"issue":"32 Pt A","key":"R5-20230912","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.vaccine.2018.02.003","article-title":"Status of HPV vaccine introduction and barriers to country uptake.","volume":"36","author":"Gallagher","year":"2018","journal-title":"Vaccine"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S2214-109X(16)30099-7","article-title":"Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis.","volume":"4","author":"Bruni","year":"2016","journal-title":"Lancet Glob Health"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.biopha.2018.06.026","article-title":"Efficacy and safety of immunological adjuvants. Where is the cut-off?","volume":"105","author":"Batista-Duharte","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2796.2011.02467.x","article-title":"Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine.","volume":"271","author":"Chao","year":"2012","journal-title":"J Intern Med"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.vaccine.2017.06.030","article-title":"Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France.","volume":"35","author":"Miranda","year":"2017","journal-title":"Vaccine"},{"key":"R10-20230912","first-page":"E194","article-title":"HPV vaccine and autoimmune diseases: systematic review and meta-analysis of the literature.","volume":"59","author":"Genovese","year":"2018","journal-title":"J Prev Med Hyg"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.vaccine.2019.04.049","article-title":"Human papillomavirus vaccination and the risk of autoimmune disorders: a systematic review and meta-analysis.","volume":"37","author":"Jiang","year":"2019","journal-title":"Vaccine"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joim.12155","article-title":"Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.","volume":"275","author":"Grimaldi-Bensouda","year":"2014","journal-title":"J Intern Med"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaut.2017.01.005","article-title":"Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance.","volume":"79","author":"Grimaldi-Bensouda","year":"2017","journal-title":"J Autoimmun"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jamaneurol.2014.2633","article-title":"Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases.","volume":"71","author":"Langer-Gould","year":"2014","journal-title":"JAMA Neurol"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.vaccine.2017.01.076","article-title":"No increased risk of Guillain-Barr\u00e9 syndrome after human papilloma virus vaccine: a self-controlled case-series study in England.","volume":"35","author":"Andrews","year":"2017","journal-title":"Vaccine"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1016\/j.vaccine.2013.08.024","article-title":"Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK.","volume":"31","author":"Donegan","year":"2013","journal-title":"Vaccine"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jama.2014.2198","article-title":"Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism.","volume":"312","author":"Scheller","year":"2014","journal-title":"JAMA"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"E648","DOI":"10.1503\/cmaj.170871","article-title":"Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study.","volume":"190","author":"Liu","year":"2018","journal-title":"CMAJ"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1016\/j.vaccine.2018.09.019","article-title":"No evidence found for an increased risk of long-term fatigue following human papillomavirus vaccination of adolescent girls.","volume":"36","author":"Schurink-Van\u2019t Klooster","year":"2018","journal-title":"Vaccine"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/cid\/ciw607","article-title":"Acute demyelinating events following vaccines: a case-centered analysis.","volume":"63","author":"Baxter","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/cid\/ciw224","article-title":"Case-centered analysis of optic neuritis after vaccines.","volume":"63","author":"Baxter","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"f5906","DOI":"10.1136\/bmj.f5906","article-title":"Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study.","volume":"347","author":"Arnheim-Dahlstr\u00f6m","year":"2013","journal-title":"BMJ"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/14760584.2018.1388168","article-title":"Absence of association between Guillain-Barr\u00e9 syndrome hospitalizations and HPV-vaccine.","volume":"17","author":"Deceuninck","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.vaccine.2017.06.031","article-title":"HPV vaccination and risk of chronic fatigue syndrome\/myalgic encephalomyelitis: a nationwide register-based study from Norway.","volume":"35","author":"Feiring","year":"2017","journal-title":"Vaccine"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/ije\/dyx273","article-title":"Quadrivalent human papillomavirus vaccination in boys and risk of autoimmune diseases, neurological diseases and venous thromboembolism.","volume":"47","author":"Frisch","year":"2018","journal-title":"Int J Epidemiol"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/joim.12694","article-title":"Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases.","volume":"283","author":"Hviid","year":"2018","journal-title":"J Intern Med"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.vaccine.2019.02.051","article-title":"Long term risk of developing type 1 diabetes after HPV vaccination in males and females.","volume":"37","author":"Klein","year":"2019","journal-title":"Vaccine"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.2014.16946","article-title":"Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.","volume":"313","author":"Scheller","year":"2015","journal-title":"JAMA"},{"key":"R35-20230912","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.1016\/j.vaccine.2018.06.074","article-title":"The association of adverse events with bivalent human papilloma virus vaccination: a nationwide register-based cohort study in Finland.","volume":"36","author":"Skufca","year":"2018","journal-title":"Vaccine"},{"key":"R36-20230912","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1080\/21645515.2017.1310788","article-title":"Evaluation of optic neuritis following human papillomavirus vaccination.","volume":"13","author":"Sridhar","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"R37-20230912","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1080\/21645515.2016.1199308","article-title":"Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16\/18 AS04-adjuvanted vaccine in the United Kingdom.","volume":"12","author":"Willame","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"R38-20230912","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/aji.12151","article-title":"Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune\/inflammatory syndrome induced by adjuvants.","volume":"70","author":"Colafrancesco","year":"2013","journal-title":"Am J Reprod Immunol"},{"key":"R39-20230912","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.2169\/internalmedicine.53.3133","article-title":"Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine.","volume":"53","author":"Kinoshita","year":"2014","journal-title":"Intern Med"},{"key":"R41-20230912","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the national influenza immunization program, United States, 1976\u20131977.","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"R42-20230912","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/aje\/kws196","article-title":"Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans.","volume":"175","author":"Wise","year":"2012","journal-title":"Am J Epidemiol"},{"key":"R44-20230912","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/art.1780370606","article-title":"The lag time between onset of symptoms and diagnosis of rheumatoid arthritis.","volume":"37","author":"Chan","year":"1994","journal-title":"Arthritis Rheum"},{"key":"R45-20230912","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/10543406.2015.1052819","article-title":"Evaluating efficiency and statistical power of self-controlled case series and self-controlled risk interval designs in vaccine safety.","volume":"26","author":"Li","year":"2016","journal-title":"J Biopharm Stat"},{"key":"R47-20230912","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1016\/j.vaccine.2013.06.032","article-title":"International collaboration to assess the risk of Guillain Barr\u00e9 syndrome following Influenza A (H1N1) 2009 monovalent vaccines.","volume":"31","author":"Dodd","year":"2013","journal-title":"Vaccine"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002569","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T18:34:14Z","timestamp":1694543654000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002569","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}